Examples include immunofluorescence for IGF-1R and the DNA damage response marker, gH2AX, in Phase I studies [28], [29], EGFR[7] and HER2[30] status in breast cancer, FISH for PTEN and FISH and RNA for TMPRSS2-ERG fusion in prostate cancer[24], [31], and genotyping for EGFR mutations in lung cancer[27]. This evidence concerns the gene ERBB2 and breast cancer.